[go: up one dir, main page]

MX2024008221A - Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico. - Google Patents

Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.

Info

Publication number
MX2024008221A
MX2024008221A MX2024008221A MX2024008221A MX2024008221A MX 2024008221 A MX2024008221 A MX 2024008221A MX 2024008221 A MX2024008221 A MX 2024008221A MX 2024008221 A MX2024008221 A MX 2024008221A MX 2024008221 A MX2024008221 A MX 2024008221A
Authority
MX
Mexico
Prior art keywords
glutathione
infections
treatment
respiratory tract
tract diseases
Prior art date
Application number
MX2024008221A
Other languages
English (en)
Inventor
Dan Copeland
Carolyn Durham
Thomas E Richardson
Original Assignee
Renovion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovion Inc filed Critical Renovion Inc
Publication of MX2024008221A publication Critical patent/MX2024008221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A01N37/30—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the groups —CO—N< and, both being directly attached by their carbon atoms to the same carbon skeleton, e.g. H2N—NH—CO—C6H4—COOCH3; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)

Abstract

La solicitud se relaciona con un método para inhibir o reducir el crecimiento de bacterias de aislado clínico que comprende poner en contacto el aislado clínico con una composición que comprende glutatión, un derivado de glutatión, un conjugado de glutatión, una sal farmacéuticamente aceptable del mismo o cualquier combinación de los mismos.
MX2024008221A 2016-11-17 2019-05-16 Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico. MX2024008221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423721P 2016-11-17 2016-11-17
US201662423702P 2016-11-17 2016-11-17

Publications (1)

Publication Number Publication Date
MX2024008221A true MX2024008221A (es) 2024-07-19

Family

ID=62146825

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005751A MX2019005751A (es) 2016-11-17 2017-11-17 Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.
MX2024008221A MX2024008221A (es) 2016-11-17 2019-05-16 Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019005751A MX2019005751A (es) 2016-11-17 2017-11-17 Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.

Country Status (11)

Country Link
US (2) US11602555B2 (es)
EP (1) EP3541401A4 (es)
KR (3) KR20230117644A (es)
CN (1) CN110198728A (es)
AU (1) AU2017362500B2 (es)
CA (1) CA3043892A1 (es)
IL (1) IL266619A (es)
MX (2) MX2019005751A (es)
NZ (1) NZ753749A (es)
WO (1) WO2018094278A1 (es)
ZA (1) ZA201903893B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117644A (ko) * 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
JP7339955B2 (ja) 2017-11-17 2023-09-06 レノビオン インコーポレイテッド 安定したアスコルビン酸組成物およびそれを使用する方法
WO2019157295A1 (en) * 2018-02-09 2019-08-15 The Trustees Of Columbia University In The City Of New York Treating infections using inhibitor of cbb3-type oxidases
CN109224062A (zh) * 2018-09-30 2019-01-18 浙江肽明生物科技有限公司 一种新型多肽高效抗菌素及其制备方法
KR102464435B1 (ko) * 2020-09-22 2022-11-07 의료법인 성광의료재단 D-글루타티온을 포함하는 염증 질환의 예방 또는 치료용 조성물
EP4460319A4 (en) * 2022-01-04 2026-01-14 Renovion Inc AQUEOUS SOLUTION CONTAINING A GLUTATHIONE SALT

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606903A (en) 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
DE2845484A1 (de) 1978-10-19 1980-04-30 Groening Ruediger Verfahren zur erhoehung der biologischen verfuegbarkeit von arzneistoffen
US5070085A (en) 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4968716A (en) 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US5304724A (en) 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ATE144142T1 (de) 1991-01-10 1996-11-15 Transcend Therapeutics Inc Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
CA2270290A1 (en) 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
CA2276183C (en) 1996-12-31 2009-06-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5829449A (en) 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US6415798B1 (en) 1997-09-19 2002-07-09 Thione International, Inc. Antioxidants to neutralize tobacco free radicals
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
WO2000007607A1 (en) 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
KR100390630B1 (ko) 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
DE19935763B4 (de) 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
EP1282416A2 (en) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
AU2002211222B2 (en) 2000-10-16 2006-02-09 Duke University Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
US20020165207A1 (en) 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
CA2470583C (en) 2001-12-18 2011-03-15 Xiangqun Gao Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
AUPS019802A0 (en) 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
CN102511498A (zh) * 2003-12-04 2012-06-27 衣阿华大学研究基金会 镓抑制生物膜形成
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
DE102004035113A1 (de) 2004-07-20 2006-02-16 Degussa Ag alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
JP5112876B2 (ja) 2004-11-07 2013-01-09 エフ． ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
JP2008520650A (ja) 2004-11-17 2008-06-19 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 疾患治療における脂質複合体の使用
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
JP2008538752A (ja) 2005-04-12 2008-11-06 クレオ コスメティック アンド ファーマスーティカルカンパニー エルエルシー 角膜組織を生体外保存するための組成物および方法
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
JP2008542208A (ja) * 2005-05-24 2008-11-27 エンバイロメンタル バイオテクノロジー シーアールシー ピーティーワイ リミテッド バイオフィルム発生を制御する方法及び組成物
US20070049641A1 (en) 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
CA2687128C (en) 2006-05-10 2017-03-28 Laclede, Inc. Compositions and methods for enzymatic treatment of lung disorders
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
WO2009023355A2 (en) 2007-05-25 2009-02-19 Ironwood Pharmaceuticals, Inc. Compositions and methods for reducing the toxicity of certain toxins
WO2009001884A1 (ja) 2007-06-26 2008-12-31 Kyowa Hakko Bio Co., Ltd. 酸化型グルタチオン錠
JP2011026204A (ja) 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
JP5406049B2 (ja) 2008-02-05 2014-02-05 協和発酵バイオ株式会社 グルタチオンの保存安定性向上方法
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
FR2941374B1 (fr) 2009-01-28 2011-03-11 Alaxia Utilisation d'une association synergique d'ions hypothiocyanites et/ou hypohalites et de lactoferrine pour la preparation pour le traitement de la mucoviscidose
WO2010099523A1 (en) 2009-02-27 2010-09-02 University Of Cincinnati Method of treating reactive airway disease
GB0908174D0 (en) 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof
US20120329675A1 (en) * 2009-07-20 2012-12-27 Olson Merle E Testing of Biofilm for Anti-microbial Agent Susceptibility
CN101987195B (zh) 2009-08-06 2012-07-18 重庆市力扬医药开发有限公司 经口腔粘膜吸收的还原型谷胱甘肽药物
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
WO2012027603A2 (en) 2010-08-26 2012-03-01 Clarity Products, Limited Liability Company Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN102100904B (zh) 2011-01-25 2013-04-24 成都卓阳生物科技有限公司 还原型谷胱甘肽经皮吸收制剂及其制备方法
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US20130084336A1 (en) 2011-06-27 2013-04-04 Albert Einstein College Of Medicine Of Yeshiva University Enhanced nitric oxide delivery and uses thereof
CN102329370B (zh) 2011-09-22 2015-07-22 山东金城医药化工股份有限公司 还原型谷胱甘肽单钠盐的制备方法
CA3153463A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2014126594A1 (en) * 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
ITPD20130052A1 (it) 2013-03-01 2014-09-02 Enologica Vason S P A Procedimento di vinificazione e prodotto per uso enologico atto ad essere utilizzato in detto procedimento di vinificazione
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016067283A1 (en) 2014-10-30 2016-05-06 Rice Howard Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2016088116A1 (en) 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CA3030971A1 (en) 2016-07-16 2018-01-25 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
KR20230117644A (ko) * 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
JP7339955B2 (ja) 2017-11-17 2023-09-06 レノビオン インコーポレイテッド 安定したアスコルビン酸組成物およびそれを使用する方法
CA3117213A1 (en) 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
EP4203928A4 (en) 2020-08-26 2024-10-09 Cila Therapeutic Inc. Inhalable therapeutic agents

Also Published As

Publication number Publication date
KR20190097022A (ko) 2019-08-20
US11602555B2 (en) 2023-03-14
US20230165929A1 (en) 2023-06-01
MX2019005751A (es) 2019-11-12
NZ753749A (en) 2025-10-31
EP3541401A4 (en) 2020-07-29
KR20260004557A (ko) 2026-01-08
AU2017362500A1 (en) 2019-06-13
EP3541401A1 (en) 2019-09-25
ZA201903893B (en) 2020-12-23
CA3043892A1 (en) 2018-05-24
IL266619A (en) 2019-07-31
WO2018094278A1 (en) 2018-05-24
KR20230117644A (ko) 2023-08-08
US12427180B2 (en) 2025-09-30
AU2017362500B2 (en) 2024-09-26
US20190351005A1 (en) 2019-11-21
CN110198728A (zh) 2019-09-03

Similar Documents

Publication Publication Date Title
MX2024008221A (es) Composicion que comprende glutation para usarse en inhibir o reducir el crecimiento de bacterias de un aislado clinico.
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CL2017003325A1 (es) Derivados de 3-tetrazolilo-benceno-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
MX392523B (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
PH12016501988A1 (en) Antibacterial compounds
MX389771B (es) Compuestos de minociclina para biodefensas.
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
MX378266B (es) Inhibidores de gingipaina de lisina.
MX376475B (es) Derivado de polimixina y usos del mismo.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos